Literature DB >> 21357846

Early determinants of pulmonary vascular remodeling in animal models of complex congenital heart disease.

Sohrab Fratz1, Jeffrey R Fineman, Agnes Görlach, Shruti Sharma, Peter Oishi, Christian Schreiber, Thomas Kietzmann, Ian Adatia, John Hess, Stephen M Black.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21357846      PMCID： PMC3873774          DOI： 10.1161/CIRCULATIONAHA.110.978528

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  63 in total

1.  Time course of endothelin-1 and nitrate anion levels after cardiopulmonary bypass in congenital heart defects.

Authors:  T Hiramatsu; Y Imai; Y Takanashi; S Hoshino; M Yashima; S A Tanaka; D Chang; M Nakazawa
Journal:  Ann Thorac Surg       Date:  1997-03       Impact factor: 4.330

2.  Decreased exhaled nitric oxide may be a marker of cardiopulmonary bypass-induced injury.

Authors:  M Beghetti; P E Silkoff; M Caramori; H M Holtby; A S Slutsky; I Adatia
Journal:  Ann Thorac Surg       Date:  1998-08       Impact factor: 4.330

3.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

Authors:  A Giaid; D Saleh
Journal:  N Engl J Med       Date:  1995-07-27       Impact factor: 91.245

4.  Common 894G>T single nucleotide polymorphism in the gene coding for endothelial nitric oxide synthase (eNOS) and risk of congenital heart defects.

Authors:  Ingrid M van Beynum; Christiaan Mooij; Livia Kapusta; Sandra Heil; Martin den Heijer; Henk J Blom
Journal:  Clin Chem Lab Med       Date:  2008       Impact factor: 3.694

5.  L-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension.

Authors:  K Howell; C M Costello; M Sands; I Dooley; P McLoughlin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-04-03       Impact factor: 5.464

6.  Plasma endothelin-1 in patients with left-to-right shunt.

Authors:  M Gorenflo; P Gross; A Bodey; L Schmitz; K Brockmeier; F Berger; G Bein; P E Lange
Journal:  Am Heart J       Date:  1995-09       Impact factor: 4.749

7.  Plasma levels of nitric oxide in children with congenital heart disease and increased pulmonary blood flow.

Authors:  Patchara Kiettisanpipop; Pornthep Lertsapcharorn; Pairoj Chotivittayatarakorn; Yong Poovorawan
Journal:  J Med Assoc Thai       Date:  2007-10

8.  Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension.

Authors:  Lesley J Millatt; Guy StJ Whitley; Dechun Li; James M Leiper; Helmy M Siragy; Robert M Carey; Roger A Johns
Journal:  Circulation       Date:  2003-09-02       Impact factor: 29.690

9.  MitoQ administration prevents endotoxin-induced cardiac dysfunction.

Authors:  G S Supinski; M P Murphy; L A Callahan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-08-05       Impact factor: 3.619

10.  The role of peroxisome proliferator-activated receptors in pulmonary vascular disease.

Authors:  Rachel E Nisbet; Roy L Sutliff; C Michael Hart
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964
View more
  7 in total

1.  Altered reactivity and nitric oxide signaling in the isolated thoracic duct from an ovine model of congenital heart disease with increased pulmonary blood flow.

Authors:  Sanjeev A Datar; Peter E Oishi; Wenhui Gong; Stephen H Bennett; Christine E Sun; Michael Johengen; Jun Maki; Rebecca C Johnson; Gary W Raff; Jeffrey R Fineman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-02-14       Impact factor: 4.733

2.  Microparticulate/Nanoparticulate Powders of a Novel Nrf2 Activator and an Aerosol Performance Enhancer for Pulmonary Delivery Targeting the Lung Nrf2/Keap-1 Pathway.

Authors:  Priya Muralidharan; Don Hayes; Stephen M Black; Heidi M Mansour
Journal:  Mol Syst Des Eng       Date:  2016-01-27

Review 3.  Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics.

Authors:  D B Frank; B D Hanna
Journal:  Minerva Pediatr       Date:  2015-01-21       Impact factor: 1.312

4.  Tezosentan increases nitric oxide signaling via enhanced hydrogen peroxide generation in lambs with surgically induced acute increases in pulmonary blood flow.

Authors:  Sanjiv Kumar; Peter E Oishi; Ruslan Rafikov; Saurabh Aggarwal; Yali Hou; Sanjeev A Datar; Shruti Sharma; Anthony Azakie; Jeffrey R Fineman; Stephen M Black
Journal:  J Cell Biochem       Date:  2013-02       Impact factor: 4.429

Review 5.  Beyond a broken heart: circulatory dysfunction in the failing Fontan.

Authors:  Makoto Mori; Alfredo J Aguirre; Robert W Elder; Ali Kashkouli; Alton Brad Farris; Ryan M Ford; Wendy M Book
Journal:  Pediatr Cardiol       Date:  2014-02-15       Impact factor: 1.655

6.  Pulmonary blood flow and pulmonary hypertension: Is the pulmonary circulation flowophobic or flowophilic?

Authors:  Thomas J Kulik
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

Review 7.  Hypoplastic left heart syndrome - unresolved issues.

Authors:  Raoul Roman Arnold; Tsvetomir Loukanov; Matthias Gorenflo
Journal:  Front Pediatr       Date:  2014-11-10       Impact factor: 3.418
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.